Business Insider29d
Jonathan Wolleben’s Positive Outlook on Structure Therapeutics, Inc. Driven by Unique Small Molecule Amylin Agonist and Promising Obesity Pipeline
Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.
Hosted on MSN2mon
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
Beyond GSBR-1290, Structure is progressing with the development of an orally administered small molecule amylin receptor agonist for obesity treatment. The company aims to finalize a development ...
FierceBiotech2d
Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
Morningstar29d
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...
Pharmabiz1mon
Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity
ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...